Results 21 to 30 of about 4,378 (208)

Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer. [PDF]

ESMO Open
Hong DS, Xu RH, Shen L, Dierselhuis MP, Orbach D, McDermott R, Italiano A, Tahara M, Bernard-Gauthier V, Neu N, Mussi CE, De La Cuesta E, Laetsch TW, Drilon A.   +13 more
europepmc   +2 more sources

Primary Resistance to Larotrectinib in a Patient With Squamous NSCLC With Subclonal NTRK1 Fusion: Case Report

JTO Clinical and Research Reports, 2023
The NTRK genes encode the TRK proteins. NTRK fusions lead to constitutively active, ligand-independent downstream signaling. NTRK fusions are implicated in up to 1% of all solid tumors and 0.2% of NSCLC.
Mary C. Boulanger, MD, Jennifer S. Temel, MD, Mari Mino-Kenudson, MD, Lauren L. Ritterhouse, MD, PhD, Ibiayi Dagogo-Jack, MD   +4 more
doaj   +1 more source

Larotrectinib Treatment of Xanthogranuloma With NTRK1 Gene Fusion: A Case Report. [PDF]

Cureus
Ralston G, Humeniuk M.
europepmc   +3 more sources

The Safety Profiles of Two First-Generation NTRK Inhibitors: Analysis of Individual Case Safety Reports from the FDA Adverse Event Reporting System (FAERS) Database

Biomedicines, 2023
The first-generation tropomyosin receptor kinase (TRK) inhibitors, larotrectinib and entrectinib, represent exciting new developments in cancer treatment that offer relevant, rapid, and long-lasting clinical benefits.
Valerio Liguori, Mario Gaio, Alessia Zinzi, Cecilia Cagnotta, Consiglia Riccardi, Giovanni Docimo, Annalisa Capuano   +6 more
doaj   +1 more source

TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs

Pharmaceuticals, 2021
Recently, two tropomycin receptor kinase (Trk) inhibitors, larotrectinib and entrectinib, have been approved for Trk fusion-positive cancer patients. Clinical trials for larotrectinib and entrectinib were performed with patients selected based on the ...
Sun-Young Han
doaj   +1 more source

Resolution on the results of Advisory Board “Searching the effective methods of testing and treating patients with NSCLC caused by NTRK gene fusions“

Медицинский совет, 2022
The Advisory Board was held on December 24, 2021. The molecular genetic research lead specialists and national lead oncologists discussed issues of diagnosis of NTRK gene translocations in patients with non-small cell lung cancer (NSCLC), as well as ...
E. V. Artamonova, V. V. Breder, L. Yu. Vladimirova, I. A. Demidova, E. N. Imyanitov, К. К. Laktionov, M. P. Matrosova, S. V. Orlov, E. О. Rodionov, D. D. Sakaeva, M. I. Sekacheva, A. V. Smolin, N. V. Fadeeva, M. L. Filipenko   +13 more
doaj   +1 more source

Larotrectinib Regimen [PDF]

, 2020
National Cancer Institute
openaire   +2 more sources

Development and validation of an LC-MS/MS method for monitoring larotrectinib, a tropomyosin-related kinase inhibitor, in mouse and human plasma and application to pharmacokinetic studies

Journal of Analytical Science and Technology, 2020
Larotrectinib is an orally administered drug and the first and only selective pan-tropomyosin receptor kinase (TRK) inhibitor in clinical development to treat cancer patients harboring a neurotrophic receptor tyrosine kinase gene fusion.
Yoon-Jee Chae, Yoo-Kyung Song, Song-Hee Chae, Min Ju Kim, Jong Soon Kang, Jae-Young Lee, Tae-Sung Koo, Kyeong-Ryoon Lee   +7 more
doaj   +1 more source

Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy

Diagnostic Pathology, 2023
Background Among the three NTRK genes, NTRK2 possesses a tremendous structural complexity and involves tumorigenesis of several types of tumors. To date, only STRN and RBPMS are identified in the fusion with NTRK2 in adult soft tissue tumors.
Ruihe Lin, Atrayee Basu Mallick, Zi-Xuan Wang, Scot Andrew Brown, Bo Lu, Wei Jiang   +5 more
doaj   +1 more source

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults

Current Oncology, 2021
The tyrosine receptor kinase (TRK) inhibitors larotrectinib and entrectinib were recently approved in Canada for the treatment of solid tumours harbouring neurotrophic tyrosine receptor kinase (NTRK) gene fusions.
D. Gwyn Bebb, Shantanu Banerji, Normand Blais, Patrice Desmeules, Sharlene Gill, Andrea Grin, Harriet Feilotter, Aaron R. Hansen, Martin Hyrcza, Monika Krzyzanowska, Barbara Melosky, Jonathan Noujaim, Bibiana Purgina, Dean Ruether, Christine E. Simmons, Denis Soulieres, Emina Emilia Torlakovic, Ming-Sound Tsao   +17 more
doaj   +1 more source